{"id":32257,"date":"2025-04-23T14:05:42","date_gmt":"2025-04-23T06:05:42","guid":{"rendered":"https:\/\/flcube.com\/?p=32257"},"modified":"2025-04-23T14:05:44","modified_gmt":"2025-04-23T06:05:44","slug":"delonix-partners-with-wuxi-vaccines-to-advance-omv-plus-platform-for-bacterial-vaccines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32257","title":{"rendered":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines"},"content":{"rendered":"\n

China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269<\/a>). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.<\/p>\n\n\n\n

Partnership and Technology<\/strong>
Under the agreement, Delonix will leverage WuXi Vaccines’ integrated development and manufacturing capabilities, as well as its world-class quality system, to enhance the OMV Plus platform. OMV Plus, launched in 2023, addresses key technical challenges in traditional OMV design and production through advanced pathogen genome editing technology. This platform enables the production of OMV, natural nanovesicles released by Gram-negative bacteria, which carry a large amount of bacterial antigens, including proteins and polysaccharides.<\/p>\n\n\n\n

Market and Public Health Impact<\/strong>
OMV technology is recognized as a promising next-generation approach for bacterial vaccines, offering solutions to the complexities of antigen screening and development. The engineered OMV platform is commercially validated and offers the advantage of inherent adjuvant properties due to its rich content of pathogen-associated molecular patterns (PAMPs), enhancing vaccine efficacy without additional adjuvants. This collaboration positions Delonix and WuXi Vaccines at the forefront of innovation in bacterial vaccine development, contributing to global public health initiatives.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a…<\/p>\n","protected":false},"author":1,"featured_media":32259,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4020,952,12,292],"class_list":["post-32257","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-delonix-bioworks","tag-hkg-2269","tag-vaccine","tag-wuxi-biologics"],"yoast_head":"\nDelonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32257\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines\" \/>\n<meta property=\"og:description\" content=\"China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32257\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T06:05:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T06:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines\",\"datePublished\":\"2025-04-23T06:05:42+00:00\",\"dateModified\":\"2025-04-23T06:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2302.webp\",\"keywords\":[\"Delonix Bioworks\",\"HKG: 2269\",\"Vaccine\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32257#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32257\",\"name\":\"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2302.webp\",\"datePublished\":\"2025-04-23T06:05:42+00:00\",\"dateModified\":\"2025-04-23T06:05:44+00:00\",\"description\":\"China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32257\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2302.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2302.webp\",\"width\":1080,\"height\":608,\"caption\":\"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32257#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines - Insight, China's Pharmaceutical Industry","description":"China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32257","og_locale":"en_US","og_type":"article","og_title":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines","og_description":"China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.","og_url":"https:\/\/flcube.com\/?p=32257","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-23T06:05:42+00:00","article_modified_time":"2025-04-23T06:05:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32257#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32257"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines","datePublished":"2025-04-23T06:05:42+00:00","dateModified":"2025-04-23T06:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32257"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32257#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp","keywords":["Delonix Bioworks","HKG: 2269","Vaccine","WuXi Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32257#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32257","url":"https:\/\/flcube.com\/?p=32257","name":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32257#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32257#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp","datePublished":"2025-04-23T06:05:42+00:00","dateModified":"2025-04-23T06:05:44+00:00","description":"China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a strategic partnership with WuXi Vaccines, a vaccine-focused contract development and manufacturing organization (CDMO) wholly owned by WuXi Biologics (HKG: 2269). This collaboration aims to advance Delonix\u2019s next-generation engineered Outer Membrane Vesicle (OMV) technology platform, OMV Plus, and drive its adoption in bacterial vaccine development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32257#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32257"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32257#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp","width":1080,"height":608,"caption":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32257#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Delonix Partners with WuXi Vaccines to Advance OMV Plus Platform for Bacterial Vaccines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2302.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32257"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32257\/revisions"}],"predecessor-version":[{"id":32260,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32257\/revisions\/32260"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32259"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}